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Spotted fever group (SFG) Rickettsia species are inoculated into the mammalian
bloodstream by hematophagous arthropods. Once in the bloodstream and during
dissemination, the survival of these pathogens is dependent upon the ability of these
bacteria to evade serum-borne host defenses until a proper cellular host is reached.
Rickettsia conorii expresses an outer membrane protein, Adr1, which binds the
complement inhibitory protein vitronectin to promote resistance to the anti-bacterial
effects of the terminal complement complex. Adr1 is predicted to consist of 8
transmembrane beta sheets that form a membrane-spanning barrel with 4 peptide
loops exposed to the extracellular environment. We previously demonstrated that Adr1
derivatives containing either loop 3 or 4 are sufficient to bind Vn andmediate resistance to
serum killing when expressed at the outer-membrane of E. coli. By expressing R. conorii
Adr1 on the surface of non-pathogenic E. coli, we demonstrate that the interaction
between Adr1 and vitronectin is salt-sensitive and cannot be interrupted by addition
of heparin. Additionally, we utilized vitroenctin-derived peptides to map the minimal
Adr1/vitronectin interaction to the C-terminal region of vitronectin. Furthermore, we
demonstrate that specific charged amino acid residues located within loops 3 and 4 of
Adr1 are critical for mediating resistance to complement-mediated killing. Interestingly,
Adr1 mutants that were no longer sufficient to mediate resistance to serum killing still
retained the ability to bind to Vn, suggesting that Adr1-Vn interactions responsible for
resistance to serum killing are more complex than originally hypothesized. In summary,
elucidation of the mechanisms governing Adr1-Vn binding will be useful to specifically
target this protein-protein interaction for therapeutic intervention.
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INTRODUCTION
Spotted Fever group (SFG) Rickettsia are Gram-negative, obligate intracellular bacteria that are
transmitted to a mammalian host when an arthropod vector takes a blood meal (Riley et al., 2012).
Members of the SFG include the human pathogens R. conorii and R. rickettsii, the etiologic agents of
Mediterranean Spotted Fever and Rocky Mountain Spotted Fever, respectively. Upon inoculation
into a host, the bacteria can spread throughout the body via the bloodstream and parasitize cells
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of many origins, including endothelial cells, monocytes,
macrophages, and hepatocytes (Walker and Gear, 1985; Walker
et al., 1994, 1999; Walker, 1997; Riley et al., 2016). Infection
of endothelial cells can lead to disruption of the endothelial
lining and increased fluid leakage which causes the characteristic
macropapular rash, thus the name Spotted Fever (Walker
and Ismail, 2008). If left untreated, infections can lead to
severe manifestations of the disease such as renal failure,
non-cardiogenic pulmonary edema, interstitial pneumonia, and
ultimately death (Walker and Ismail, 2008). When rickettsial
infection is properly diagnosed, treatment is generally successful;
however, misdiagnosis is common due to initial non-descript
flu-like symptoms, which leads to increased morbidity and
mortality (Chan et al., 2009; Riley et al., 2014).
Because of the obligate intracellular nature of SFG rickettsia,
the bacteriamust bind to and invade a host cell in order to survive
and proliferate (Walker and Ismail, 2008). However, during
arthropod feeding and rickettsia dissemination, the bacteria are
extracellula and as a result are exposed to the hostile environment
of the mammalian bloodstream (Riley et al., 2014). While outside
the safety of the host cell cytosol, the bacteria are exposed to
the bactericidal effects of the host’s complement system and
survival of these bacteria are dependent upon their ability to
evade killing until a proper cellular host is reached (Riley et al.,
2012).
The complement system contributes to both the innate and
adaptive immune system, and serves as the first line of defense
against invading organisms. Complement is composed of fluid-
phase and membrane bound proteins that can be activated
through three different mechanisms (Singh et al., 2010a). The
classical, the lectin, and the alternative pathways are initiated by
antibodies or various proteins that recognize structures on the
surface of a microbe and the pathways converge at the formation
of C3 convertase to form the common lytic pathway (Blom et al.,
2009). This results in the deposition of membrane attack complex
(MAC) proteins C5b through C9 on the surface of the pathogen
and accumulation of these proteins leads to formation of a lytic
pore in the membrane which causes osmotic cell lysis (Singh
et al., 2010b). Other functions of complement include increased
opsonization of the pathogen by binding of C3b components
to the surface of the microbe and stimulation of inflammatory
responses with the proteins C3a, and C5a (Blom et al., 2009).
The complement cascade must be kept under strict control,
bercause activation can result in significant inflammation and
can attack both foreign molecules as well as a self components.
As such, the host utilizes a series of regulatory proteins which
include Factor I, Factor H, C4-binding protein, vitronectin, and
clusterin (Singh et al., 2010b). These proteins associate with the
surface of host cells in order to control and block complement
activation (Hallstrom et al., 2015). Many bacterial pathogens,
including Moraxella catarrhalis, Neisseria meningitidis,
Streptococcus pyogenes, S. pneumoniae, Staphylococcus aureus,
and Pseudomonas aeruginosa have evolved mechanisms to
utilize these host regulatory proteins to their advantage, thereby
protecting themselves from complement-mediated attacks
(Liang et al., 1997; Singh et al., 2010a; Griffiths et al., 2011; Voss
et al., 2013; Riley et al., 2014; Hallstrom et al., 2015).
A previous report demonstrated that R. conorii is inherently
resistant to complement-mediated killing when exposed to
human serum (Chan et al., 2011). This information led to the
discovery of a protein that is expressed on the surface of R.
conorii, termed Adr1, that contributes to the serum resistance
phenotype by binding the multifunctional human glycoprotein
vitronectin (Riley et al., 2014). Vitronectin binds to complement
proteins C5b-C7 and C9 to inhibit deposition of the MAC on the
bacterial surface (Singh et al., 2011). The R. conorii vitronectin-
binding protein, Adr1, is a conserved outer membrane protein
that is predicted to contain 8 trans-membrane beta sheets that
form a membrane spanning barrel, as well as four connecting
beta strands termed “loops” that protrude into the extracellular
environment (Vogt and Schulz, 1999; Riley et al., 2014). Our lab
previously demonstrated that two of these domains, loops 3 and
4, were sufficient to interact with vitronectin and thus, mediate
resistance to serum killing when Adr1 proteins containing
either loop 3 or loop 4 were expressed in a serum-sensitive
strain of E. coli (Riley et al., 2014). Interestingly, homologs
of Adr1 are present in every sequenced rickettsial species
to date and the deduced amino acid sequences of loops 3
and 4 are almost 100% conserved among SFG rickettsial
species (Riley et al., 2014), suggesting that resistance to serum
mediated killing mediated by Adr1 may be a widespread
virulence attribute in this class of obligate intracellular
pathogens.
In the present study, we further analyzed the interaction
between Adr1 and vitronectin with the intention of
understanding in detail the mechanisms of interaction. We
demonstrated that the interaction of Adr1 with vitronectin is
sensitive to increasing salt concentrations, and not competitively
inhibited by increasing concentrations of heparin. Using
various truncated, recombinant vitronectin peptides, we also
demonstrate that the Adr1-vitronectin interaction maps to
a region located in the C-terminal domain of vitronectin.
Furthermore, we utilized site-directed mutagenesis to determine
the specific amino acids located within loops 3 and 4 of Adr1
that are critical in mediating resistance to complement-mediated
killing in serum.
MATERIALS AND METHODS
Construction of Mutants in Adr1 by PCR
Plasmids pJP01-L3 and pJP01-L4 as previously described (Riley
et al., 2014) were utilized as a template for quick-change site-
directed mutagenesis PCR to mutate individual lysine residues
in each loop to alanine residues. Briefly, plasmids pJP01-L3 and
pJP01-L4 contain the gene for an Adr1 derivative with only
intact loop 3 or loop 4, respectively. All other loops have been
reduced to the bare minimum amino acids necessary to maintain
structural integrity of the protein (Riley et al., 2014). Primers for
mutations can be found in Supplemental Table 1. In each case,
parental DNA was digested using DpnI leaving mutant plasmid,
which was then transformed into MaxEfficiency DH5-alpha-T1
(Life Technologies) and sequenced.Mutants were constructed for
single amino acid substitutions as well as multiple and multiple,
sequential amino acid substitutions for all 6 lysine residues in
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pJP01-L3 and pJP01-L4. Amino acid mutations are designated in
Figure 3.
Bacterial Strains and Culture Conditions
E. coli BL21 (DE3) (pJP01, pJP01-L3, pJP01-L4, pET22b, pJP01-
L3 mutants, and pJP01-L4 mutants) were cultured in Luria-
Bertani (LB) broth at 37◦C with 50 µg/mL of carbenicillin
overnight. Bacteria were then diluted 1:10 into fresh media
and grown to an OD600 between 0.5 and 1.0. Protein
expression was induced with 0.6 mM IPTG (Isopropyl β-D-1-
thiogalactopyranoside) and cultures were grown for 4 h at 37◦C.
Antibodies
Rabbit Anti-Adr1 peptide polyclonal antibodies (pAb) were
utilized for immunoblot analysis of Adr1-expressing E. coli
as previously described (Riley et al., 2014). Anti-E. coli RNA
polymerase monoclonal IgG3 antibody (Ab) was purchased from
Affinity Bioreagents. Rabbit IgG anti-human vitronectin pAb was
purchased from Complement Technology and sheep anti-human
vitronectin IgGwas fromAbD Serotec. Mouse IgG anti-Histidine
tag pAb directly conjugated to horseradish peroxidase (HRP)
was purchased from GenScript. Both donkey anti-mouse IRDye
680 IgG and donkey anti-rabbit IRDye 800 IgG were purchased
from LiCOR biosciences. HRP-conjugated goat anti-rabbit IgG
was from Sigma and donkey anti-sheep IgG was purchased from
Thermo-Fisher.
Vitronectin Binding Assay
To evaluate vitronectin binding, E. coli BL21 (DE3) containing
plasmids pJP01, pET22b, or mutants were grown as described
previously. Approximately 1 × 106 colony forming units (cfu)
of each construct was washed with PBS and resuspended in 200
µL PBS containing 25% normal human serum (NHS) pooled
from 5 healthy individuals (Innovative Research). For analysis
of vitronectin binding in the presence of NaCl or heparin,
NaCl was purchased from Fisher Chemical and Heparin Sodium
Salt was purchased from MP Biomedicals, LLC. The Adr1 and
mutant expressing bacteria were resuspended in 100 µL PBS
containing increasing concentrations of either NaCl (0, 0.25,
0.50, or 1.0M) or heparin (0, 1, 2, 4, 8, 12, 16, 20, or 500
nM). One hundred microliter of 50% NHS was then added
to the heparin/E.coli or NaCl/E.coli solution for final NHS
concentration of 25%. For analysis of binding of vitronectin
peptides, 1 × 106 cfu Adr1 expressing E. coli were resuspended
in a 100 µL of a 5 µM solution of each indicated purified
recombinant peptide that had been expressed and isolated from
HEK293T cells (Singh et al., 2010a). For analysis of vitronectin
binding to R. conorii, a live, frozen stock of R. conorii was
allowed to come to room temperature and resuspended in 50
µL of a heparin or salt solution at concentrations previously
mentioned and 50 µL of 50% NHS was added for a final NHS
concentration of 25%. To assess differences in multimeric and
monomeric vitronectin binding to mutant expressing E. coli,
multimeric, and monomeric vitronectin were purchased from
Innovative Research. Roughly 1 × 106 cfu of Adr1 and mutant
expressing bacteria were washed and resuspended in 25 µL
of PBS. Twenty five microliter of 50 ng/mL of monomeric or
multimeric vitronectin was then added for a final concentration
of 25 ng/mL vitronectin. Adr1 expressing E. coli were incubated
on ice when bacteria were resuspended in NHS whereas bacteria
resuspended in monomeric, multimeric, or recombinant peptide
vitronectin were incubated at room temperature. R. conorii were
also incubated at room temperature. All samples were allowed to
bind for 1 h with gentle agitation, bacteria were washed 3 times in
PBS and vitronectin binding was determined by SDS-PAGE and
western immunoblotting using rabbit anti-human vitronectin or
sheep anti-human vitronectin as primary antibody and goat anti-
rabbit IgG HRP or donkey anti-sheep IgG HRP as secondary
antibody.
Serum Resistance Assay
NHS pooled from 5 healthy individuals (NHS) (Innovative
Research) was stored at −80◦C as aliquots until use. E. coli BL21
(DE3) containing pJP01-L3, pJP01-L4, pET22b, or loop 3 and
loop 4 mutants were grown as described above. Approximately
1 × 106 bacteria were then washed with PBS and resuspended
in either 200 µL of PBS or 200 µL PBS containing 10% NHS.
Bacteria were incubated at 37◦C for 15 min with agitation and
then serially diluted in PBS and plated on LB-Agar plates. After
overnight incubation, colony-forming units (cfu) were evaluated.
Experiments were performed in triplicate with a minimum of
3 replicates for each experiment. Data is presented as the cfu
of bacteria in PBS/cfu of bacteria in 10% NHS after 15 min of
incubation and plotted on a logarithmic scale. Expression of Adr1
or Adr1mutant proteins was verified by western immunoblotting
using rabbit anti-Adr1 or mouse anti-histidine tag antibodies as
described above.
Bacterial Fractionation
Induced E. coli BL21 (DE3) cultures (250 mL) were pelleted,
resuspended in 5 mL PBS containing 1x protease inhibitor
cocktail and then fractionated to enrich for outer-membrane
proteins as described (Hancock and Nikaido, 1978). Briefly,
bacteria were twice lysed in a French Pressure cell (1,500 psi)
and unbroken cells were cleared by centrifugation at 3,000 g for
15 min at 4◦C. Sarkosyl was added to the resulting supernatant
(total cell lysate) to a final concentration of 0.5% and incubated
with rotation at room temperature for 10 min to extract inner
membrane proteins. Outer membrane proteins were pelleted
by ultracentrifugation for 1 h at 100,000 g and resuspended in
2x sample buffer. Total cell lysate, inner membrane fraction
and outer membrane fraction were resolved by SDS-PAGE and
stained with Coomassie blue for visualization of total protein
content and analyzed by western immunoblotting with anti-Adr1
antibodies.
Statistical Analysis
Statistical Analysis was performed using a one-way ANOVA
with a Neuman-Keuls post hoc test or a Kruskal-Walis one-
way ANOVA test to compare differences between more than
two groups as indicated. Differences were considered significant
with a p-value less than or equal to 0.05 using Graph-Pad Prism
version 5.0b (GraphPad Software).
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RESULTS
Vitronectin Binding Is Significantly
Reduced by Increasing Concentrations of
NaCl, but Is Not Substantially Inhibited by
Heparin
Vitronectin contains many different functional regions that
mediate its various roles in the human host (Singh et al.,
2010a). Heparin-binding domains have been demonstrated to
be involved in the interaction between vitronectin and Outer-
membrane protein C (Opc) of N. meningitis, Ubiquitous surface
protein A2 (UspA2) of M. catarrhalis, Lpd of P. aeruginosa,
and several other pathogenic bacteria (Sa et al., 2010; Griffiths
et al., 2011; Hallstrom et al., 2015). The charge of the
individual amino acid residues within the binding domains of
the outer membrane proteins of S. pneumoniae andHaemophilus
influenzae have also been documented to play a role in
binding (Hallstrom et al., 2009; Voss et al., 2013). Because
of the high concentration of positively charged lysine residues
located within loops 3 and 4 of Adr1, we hypothesized that
these residues would play an important role in the protein-
protein interaction. To determine if the R. conorii Adr1/human
vitronectin interaction is a result of Adr1 interacting with the
heparin binding domains or is an electrostatic interaction, Adr1
was expressed at the surface of E. coli and exposed to human
serum in the presence of either increasing concentrations of
heparin or NaCl. As the concentration of heparin in solution
was increased 0–500 nM, which is approximately 3 times
the concentration found in human plasma (Engelberg, 1961),
there was no significant difference in ability of vitronectin
to bind to Adr1 (Figure 1A and Supplemental Figure 1A).
In contrast, increasing concentrations of NaCl in solution
ranging from 0 to 1 M in the reaction, competitively inhibited
the interaction between vitronectin and Adr1 (Figure 1B
and Supplemental Figure 1B). Interestingly, when increasing
concentrations of both NaCl or heparin were added to intact R.
conorii cells in the presence of NHS, there was no significant
difference in the ability of vitronectin to bind to R. conorii
(Figures 1C,D and Supplemental Figures 1C,D). These data
suggest that R. conorii and other pathogenic rickettsial species
may possess additional factors that are sufficient to interact with
vitronectin and may contribute to this phenotype. Nevertheless,
this data suggests that the heparin-binding domains of
vitronectin are not involved in the Adr1/vitronectin interaction,
and that specific charged amino acid residues in loops 3 and 4 are
likely critical in mediating this protein-protein interaction.
Adr1 Binds within the C-Terminal Region of
Vitronectin between Amino Acids 363 and
373
We next wanted to identify the region(s) within vitronectin
that mediate binding to Adr1. The C-terminal region (amino
acids 312–396 depicted in Figure 2A) of vitronectin is well
documented to mediate binding of serum resistance proteins
from bacterial pathogens such as Protein E from H. influenzae,
UspA2 from M. catarrhalis, and the PspC protein from S.
pneumoniae (Singh et al., 2010a, 2011; Griffiths et al., 2011; Voss
et al., 2013; Hallstrom et al., 2016). Because this region plays
an important role in many interactions of both Gram-negative
and Gram-positive bacteria, we hypothesized that Adr1 would
also bind within the C-terminal region. To test this hypothesis,
we performed vitronectin binding assays using a series of
FIGURE 1 | Vitronectin binding to E. coli expressing Adr1 or R. conorii. (A,B) Western immunoblot analysis of vitronectin binding to E. coli expressing Adr1 in
the presence of increasing concentrations of heparin (0–500 nM) or NaCl (0–1 M). Equal loading in each experiment was verified using an E. coli RNA polymerase
antibody. Verification of Adr1 expression was validated using anti-Adr1. Data are representative of at least 3 independent experiments. (C,D) Western immunoblot
analysis of vitronectin binding to R. conorii in the presence of increasing concentrations of heparin or NaCl. Equal loading in each experiment was verified using
anti-OmpB and anti-Adr1 antibodies. Data are representative of 2 replicates.
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FIGURE 2 | Functional domains in vitronectin and peptides constructed for analysis of Adr1 binding region. (A) Full length vitronectin with noted functional
domains is depicted in the top black arrow with the constructed peptides depicted in gray arrows below. (B) Silverstain of vitronectin peptides utilized. The first 8
peptides begin at amino acid 80 and are progressively truncated at the C-terminus. The 3 full length peptides contain a deletion within the C-terminal region.
(C) E. coli expressing Adr1 binds to the 3 longest vitronectin peptides and the full length peptide with a deletion at amino acids 352–362. Equal loading is
demonstrated with anti-E. coli RNA polymerase and verification of expression of Adr1 is verified using anti-Adr1. Data are representative of at least 3 replicates.
recombinant, truncated vitronectin peptides demonstrated in a
silver stain in Figure 2B (Singh et al., 2010a; Su et al., 2013)
and Adr1-expressing E. coli BL21(DE3). As shown in Figure 2C,
peptides Vn 80–396, Vn 80–379, Vn 80–373, and Vn 1352–362
were sufficient to bind to Adr1 expressed at the outer membrane
of E. coli. Our data demonstrates that the region between amino
acid 363 and 373 within the C-terminal region of vitronectin is
involved in the binding of Adr1 and further demonstrate that
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5 March 2017 | Volume 7 | Article 61
Fish et al. Characterization of Adr1-Vitronectin Interactions
Adr1-vitronectin interactions do not require heparin-binding
domains.
Serum Survival of E. coli Expressing Adr1
Lysine to Alanine Mutants
We have previously demonstrated that extracellular Adr1 loops 3
and 4 are sufficient to both mediate resistance to complement-
mediated killing and bind vitronectin (Riley et al., 2014). We,
therefore, sought to identify residues within each loop that
were responsible for the interaction. We utilized the previously
constructed plasmids, pJP01-L3, and pJP01-L4 (Riley et al.,
2014) which encode Adr1 proteins expressing only loops 3
or 4, respectively as templates for site-directed mutagenesis
to substitute positively charged lysine residues to uncharged,
non-polar alanine residues. A summary of the constructs used
in these experiments is depicted in Figure 3. We initially
verified expression of each construct by transforming a serum-
sensitive strain of E. coli BL21 (DE3) with the indicated
plasmid and inducing protein expression as described above.
Western immunoblotting with anti-Adr1 antibodies confirmed
the expression of each construct (Supplemental Figures 2, 3).
Constructs pAF15, pAF16, pAF25, pAF28, and pAF29 did not
express under any condition tested and were not further utilized.
Because our data demonstrated that Adr1-Vn interactions are
electrostatic in nature and that the Vn-interacting domains of
Adr1 (loops 3 and 4) contain a high concentration of positively
charged amino acids, we hypothesized that removal of one or
more of the positive charge would decrease the ability of Adr1-
expressing E. coli to survive when exposed to serum and to
interact with Vn. To initially determine serum survival, each
Adr1 mutant was expressed in E. coli and incubated in 10%
NHS in PBS and PBS alone as a control. The cfu of bacteria
exposed to NHS were quantified in comparison to the bacteria
exposed to PBS and bacterial survival was expressed as the
percent bacteria remaining after exposure to serum. As shown
in Figures 4A,D, Adr1 mutants containing a single lysine to
alanine substitution in any position within each loop remained
resistant to serum killing. In contrast, when the first two or
more positive charges to uncharged substitutions were made,
the ability of E. coli expressing Adr1 mutant proteins to resist
serum killing was significantly decreased (Figures 4B,C,E,F).
These results suggest that the first two lysines in either loops
3 or 4 are critical to mediate resistance to serum mediated
killing, but do not exclude the possibility that the net charge in
either Adr1 loop contributes to the observed phenotype. We,
therefore, designed experiments to distinguish between these two
possibilities. Using the Adr1-loop 3 construct as a model, we
created double lysine mutants at lysine positions 1 and 5 or
at positions 5 and 6 (Figure 3), expressed these mutant Adr1
proteins in E. coli, and tested for their ability to survive in NHS.
As shown in Figure 5, E. coli expressing the indicated lysine to
alanine substitutions in Adr1 were able to survive when exposed
to human serum. Taken together, these data demonstrate that the
first two lysine residues in loop 3 are critical to mediate resistance
to complement mediated killing, and suggests that these residues
may play important roles in the interaction with vitronectin.
Binding of Multimeric Vitronectin Is
Correlated with Survival of
Adr1-Expressing Bacteria
We next sought to verify that the serum-resistant phenotypes
are correlated with the ability of Adr1 to bind vitronectin. We
hypothesized that E. coli expressing Adr1 mutants that survived
serum killing were sufficient to bind vitronectin, while E. coli
expressing Adr1 mutants that did not survive in serum were
either unable to bind or are greatly impaired in their ability
to bind vitronectin. To test this hypothesis, we transformed E.
coli BL21(DE3) with the constructs for serum resistant Adr1
loop 3 proteins harboring a single amino acid substitution
construct, representing serum resistant phenotypes (pAF1 and
pAF2), the double amino acid constructs at positions 1 and 5
(pAF53) and at position 5 and 6 (pAF55). Plasmids encoding
for serum-sensitive phenotypes were also transformed, and
include double substitution at positions 1 and 2 construct
(pAF13) and triple substitution at positions 1, 2, and 3 construct
(pAF14), representing the serum sensitive phenotype. Adr1 loop
4 mutant proteins containing a single amino acid substitution
(pAF8, serum resistant) and the double and triple mutants
(pAF17 and pAF26, serum-sensitive) were also expressed in
E. coli. We initially verified the expression of Adr1 mutants
at the outer membrane of E. coli when expressed under
these conditions (Supplemental Figure 4). These bacteria were
FIGURE 3 | Schematic representation of K-A substitutions in R. conorii Adr1 loops 3 and 4. The position of each substituted lysine in loops 3 and 4 and the
corresponding name of the plasmid is depicted above.
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FIGURE 4 | Analysis of loop 3 and 4 mutant Adr1 serum resistance when expressed on the surface of E. coli and exposed to NHS. (A,D) A single lysine to
alanine substitution (AF2 and AF7). (B,E) A double lysine to alanine substitution at positions 1 and 2 (AF13 and AF17). (C,F) A triple amino acid substitution at
positions 1, 2, and 3 (AF14 and AF24). Data are representative of at least 3 replicates. A one-way ANOVA with a Newman-Keuls post hoc test was performed.
*Represent a p ≤ 0.05 and is considered significant. ns represents no significance.
FIGURE 5 | Analysis double mutants of loop 3 Adr1 serum resistance when expressed on the surface of E. coli and exposed to NHS. (A) A double lysine
to alanine substitution at positions 1 and 5 (AF53). (B) A double lysine to alanine substitution at positions 5 and 6 (AF55). Data are representative of at least 3
replicates. A one-way ANOVA with a Newman-Keuls post hoc test was performed. *Represent a p ≤ 0.05 and is considered significant. ns represents no significance.
incubated with NHS, and analyzed for their abilities to interact
with humanVn via aWestern immunoblot analysis. Surprisingly,
E. coli expressing either serum-resistant or serum-sensitive Adr1
mutant constructs were able to bind Vn in serum (Figures 6A,B).
Vitronectin within the blood exists in both a monomeric
and multimeric form. Consequently, Vn interactions that are
responsible for Adr1-mediated serum resistance may in part
be dependent on the form with which Adr1 interacts. Because
the vitronectin multimer is the functionally active form we
hypothesized that serum resistant mutants were able to bind
to the multimeric form of Vn while serum-sensitive mutants
were unable or significantly reduced in the ability to bind
to the multimer. We also hypothesized that all mutants
representing both serum-resistant and sensitive phenotypes
would bind to the vitronectin monomer. To test our hypotheses,
the aforementioned constructs were expressed at the outer
membrane of E. coli. The bacteria were then incubated with
monomeric and multimeric vitronectin and analyzed for the
ability to bind to each form. The results of our experiment
demonstrated that serum-resistant mutants bound to multimeric
vitronectin (Figures 7A,C) whereas serum-sensitive mutants had
a decreased ability to bind to the multimer. Conversely, all
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 7 March 2017 | Volume 7 | Article 61
Fish et al. Characterization of Adr1-Vitronectin Interactions
FIGURE 6 | Serum resistance or sensitivity does not correlate with the ability to bind vitronectin in serum. (A,B) Western immunoblot analysis of vitronectin
in serum binding to E. coli expressing loop 3 or loop 4 Adr1 mutants with both serum resistant and serum-sensitive phenotypes. Equal loading was verified using
anti-E. coli RNA polymerase and Adr1 expression was verified using anti-Adr1. Data are representative of at least 3 replicates. Arrows depict Adr1 constructs that
confer resistance to serum killing.
FIGURE 7 | Analysis of monomeric and multimeric vitronectin binding to loop 3 and 4 mutants. (A,C) Western immunoblot analysis of multimeric vitronectin
binding to E. coli expressing loop 3 or loop 4 Adr1 mutants with both serum resistant and serum-sensitive phenotypes. (B,D) Western immunoblot analysis of
monomeric vitronectin binding to E. coli expressing loop 3 or loop 4 Adr1 mutants with both serum resistant and serum-sensitive phenotypes. Equal loading was
verified using anti-E. coli RNA polymerase and Adr1 expression was verified using anti-Adr1. Data are representative of at least 3 replicates. Arrows depict Adr1
constructs that confer resistance to serum killing.
mutant regardless of phenotype were able to sufficiently bind
to monomeric vitronectin (Figures 7B,D). These data indicate
that electrostatic Adr1-Vn interactions are important for serum
resistance and specifically serum resistance can be correlated with
the ability of the bacteria to bind to the multimeric form of
human vitronectin.
DISCUSSION
A previous report from this laboratory demonstrated that
R. conorii binds vitronectin (Vn) to facilitate evasion of
complement-mediated killing (Riley et al., 2014). Additionally,
Adr1 loops 3 and 4 were sufficient to mediate the interaction
with Vn. In the present study, we focused on elucidating the
molecular determinants of the Adr1/vitronectin protein/protein
interaction. Human vitronectin is a multifunctional human
glycoprotein that is part of both the extracellular matrix
and found in plasma. This protein plays a role in many
biological functions including cell migration, tissue repair, and
regulation of MAC formation by binding C5b-C7 complex
and inhibition of C9 deposition on the surface of a cell or
microbe (Singh et al., 2010b; da Silva et al., 2015). Vitronectin
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has a multi-domain structural arrangement that consists of an
N-terminal somatomedian B domain which binds plasminogen
activator inhibitor-1 and an RGD (arginine, glycine, and aspartic
acid) domain that interacts with several integrins thereby aiding
in attachment (Blom et al., 2009). Vitronectin also contains
three heparin-binding domains and a C-terminal region with
an unknown function, both of which have been shown to bind
to surface proteins of bacterial pathogens (Blom et al., 2009;
Singh et al., 2010a, 2011). Homologs to human vitronectin are
found among many mammalian species including rabbits, mice,
and cows. Interestingly, when these mammalian vitronectin
proteins are compared there are regions of variability in both
the N- and C-termini. Human vitronectin contains several
unique residues within the C-terminal region, which may play
an important role in protein-protein interactions (Leduc et al.,
2009; da Silva et al., 2015). Because vitronectin is one of
the major regulators of MAC formation, it plays a critical
role in deposition of the MAC on bacterial pathogens. Gram-
negative pathogens including R. conorii, Legionella pneumophila,
Neisseria meningitidis, Pseudomonas aeruginosa, M. caterrhalis,
and H. influenzae utilize vitronectin to protect against MAC
killing (Hallstrom et al., 2006, 2009, 2016; Singh et al., 2010a;
Riley et al., 2014). On the other hand, Gram-positive bacteria
such as S. pneumoniae and S. pyogenes utilize vitronectin as a
bridge to bind to and invade host cells (Leroy-Dudal et al., 2004;
Singh et al., 2010b).
Our results indicate that the Adr1/Vn interaction is a
heparin-independent, electrostatic interaction based on the
ability of increasing concentrations of NaCl, but not heparin
to inhibit the interaction between the two proteins. The
ability of the recombinant peptide that contains a deletion
within the C-terminal heparin binding domain (352–362) to
bind to Adr1 when expression on the surface of E. coli
further supports our conclusion that the Adr1/Vn interaction
is heparin-independent. To our knowledge, this is the first
demonstration of an outer-membrane protein in a Gram-
negative bacterial pathogen that interacts with vitronectin in a
heparin-independent, salt-sensitive manner. Heparin-dependent
interactions, on the other hand, are well documented in Gram-
negative pathogens (Hallstrom et al., 2016) and include proteins
such as Ubiquitous surface protein A2 (UspA2) of M. catarrhalis,
Haemophilus surface fibrils (Hsf) of H. influenzae type B,
and Protein E (PE) and Protein F (PF) from non-typable
H. influenzae (NTHi) (Hallstrom et al., 2006; Singh et al., 2010a,
2011; Su et al., 2013). Interestingly, a Gram-negative pathogen,
N. meningititis, interacts with vitronectin via Meningococcal
surface fibrils (Msf) in a heparin-independent manner; however,
salt dependence has yet to be determined (Griffiths et al.,
2011). Similarly to the Adr1/vitronectin interaction in R.
conorii, the Gram-positive pathogen, S. pneuomiae interacts
with vitronectin via Pneumococcal surface protein C (PspC) in
a salt sensitive manner, signifying an electrostatic interaction.
Increasing concentrations of salt competitively inhibited the
ability of vitronectin to bind to PspC suggesting that the
negatively charged amino acids in PspC mediate this interaction;
however, individual amino acids responsible for this interaction
have yet to be identified (Voss et al., 2013). The Adr1/Vn
interaction is different from other bacterial/Vn interactions, and
is likely unique to the Rickettsiales.
We utilized recombinant vitronectin peptides to elucidate the
Vn region(s) required for association with Adr1. This region
(amino acids 312–396) plays an important role in binding surface
exposed proteins of both Gram-negative and Gram-positive
bacterial pathogens (Singh et al., 2010a, 2011; Su et al., 2013; Voss
et al., 2013; Hallstrom et al., 2016). Like many other bacterial
pathogens, Adr1 from R. conorii was demonstrated to bind
within the C-terminal region of vitronectin (amino acids 363–
373), adjacent to the third heparin-binding domain. In contrast,
many gram-negative and gram-positive bacteria including S.
pneumoniae, H. influenzae P. aeruginosa, Staphlococcus aureus,
S. pyogenes all of which have heparin-dependent interactions
with vitronectin, bind within a domain (amino acids 352
and 374) containing a portion of the third heparin-binding
domain (Hallstrom et al., 2006, 2016; Singh et al., 2011; Voss
et al., 2013). H. influenzae also utilizes a heparin-mediated
interaction with vitronectin, but the region required for binding
to PE encompasses a longer sequence (amino acids 353–396)
(Hallstrom et al., 2009, 2016).
A few other electrostatic protein-vitronectin interactions have
been described. For example, the Gram-positive pathogen, S.
pneumoniae utilizes PspC to bind vitronectin in a salt-sensitive
manner. Although individual amino acids responsible were not
identified, researchers suspect the negatively charged amino
acids of the R domain in PspC mediate this interaction (Voss
et al., 2013). In addition, the Gram-negative pathogen, H.
influenzae binds vitronectin via PE in a heparin-dependent
manner; however, two amino acids, leucine 85 and arginine
86 have been identified as critical for this interaction (Singh
et al., 2011). Although leucine is an uncharged non-polar
residue, arginine is positively charged and this charge could
possibly contribute to the interaction. We determined that the
Adr1/vitronectin interaction was an electrostatic interaction that
was not mediated by a single charged residue. Instead, we
observed that a substitution in the first two lysine residues in
loops 3 and 4 caused a significant decrease the inability of E. coli
expressing these proteins to evade the bactericidal effects of NHS.
It is possible that these 2 amino acids in each loop independently
create a critical initial interaction domain that is necessary for
stable Adr1-vitronectin interactions and that without these two
residues, Adr1 is not able to effectively mediate this protein-
protein interaction. This hypothesis is further supported by the
observation that perturbing the overall charge in Adr1 loop 3
had no deleterious effect on the ability of E. coli expressing this
protein to survive serum-mediate killing.
Surprisingly, our results did not demonstrate a direct
correlation between the ability to bind Vn and the ability to
mediate survival in serum. Within human serum, vitronectin
exists in both a monomeric and a multimeric form. The
predominant form in plasma is a monomer and is also referred
to as the “native” form (Stockmann et al., 1993). Multimeric
vitronectin is found in small quantities, and consists of intra-
molecular interactions between monomers (Stockmann et al.,
1993). Previous studies examining vitronectin binding to outer-
membrane proteins of various other pathogenic bacteria have
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looked at the native versus active form. The native form of
vitronectin is folded, whereas the active form is conformationally
altered and has an “open” structure, meaning that certain cryptic
epitopes are available that are likely masked in the native form (Sa
et al., 2010). Human serum is predicted to contain more than 7%
of the activated form of vitronectin (Sa et al., 2010). Interestingly,
the outer membrane protein, Opc of N. meningitidis exhibits
preferential binding to the active form of vitronectin to mediate
adhesion and invasion of brain cells (Sa et al., 2010). Conversely,
Yersinia pestis utilizes two outer membrane proteins, Ail and
Pla, to bind and proteolytically process the native form of
vitronectin to facilitate resistance to complement mediated
killing (Bartra et al., 2015). Upon further testing, we were
demonstrated that serum-resistant Adr1 mutants bound both
multimeric andmonomeric Vn whereas serum-sensitive mutants
bound to monomeric Vn, but were substantially impaired in
their ability to bind to multimeric Vn. The data suggests that
multimeric vitronectin mediates protection from complement-
mediated killing. Therefore, vitronectin interactions that are
responsible for Adr1-mediated serum resistance are dependent
on the form with which Adr1 interacts. It is apparent that the
critical Adr1-vitronectin interaction that contribute to R. conorii
survival in serum is much more complex than originally thought.
Recent analysis of patients with confirmed cases of R.
conorii infection demonstrated increased serum concentration
of complement activation markers (Otterdal et al., 2016).
The logical conclusion from those studies is that R. conori
infection activates complement, potentially leading to release
of inflammatory cytokines, and chemokines, and increases
monocyte activation (Otterdal et al., 2016). While this data
may appear to be contrary to our findings, a cursory glance
at the complement cascade demonstrates that this is not
the case. Herein and in previous publications, we describe
rickettsial mechanisms for avoiding killing in serum. The
Adr1/Vn interaction simply implies that, regardless of the state
of complement activation, R. conorii is able to prevent activation,
and deposition of the antibacterial terminal complement
complex. As such, the findings of Otterdal et al. dovetail with
our results, because in vivo complement activation indicates that
R. conorii must avoid complement-mediated killing in order to
establish (Riley et al., 2012, 2014).
Neisseria meningitidis is a human pathogen that causes
increased morbidity and mortality worldwide as a result of sepsis
and meningitis. Like R. conorii, N. meningitidis has the ability
to bind to complement regulatory proteins in order to avoid
complement mediated killing. Specifically, this bacteria binds
Factor H via factor H-binding protein to avoid deposition of
C3b and activation of the alternative arm of the complement
system (Madico et al., 2006). When antibodies were created
against this protein, the ability of the bacteria to bind Factor
H was significantly decreased and as a result, the bacteria
were not able to survive in serum (Madico et al., 2006). This
discovery lead to the development of a preventative vaccine
against multiple strains of N. meningitidis directed against factor
H-binding protein (Seib et al., 2015; Gandhi et al., 2016). Herein,
we demonstrate the molecular determinants of the interaction
between R. conorii Adr1 and human Vn. The results gathered
from this work further contribute to our understanding of the
molecular mechanisms by which pathogenic rickettsial species
establish successful infections in mammalian hosts. Elucidation
of the interacting interface(s) in Adr1 and vitronectin will
hopefully better guide the development of novel and efficacious
anti-rickettsial therapies that specifically target this important
protein-protein interaction.
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Supplemental Figure 1 | Densitometric Analysis of Vitronectin binding.
(A,B) Densitometric analysis of vitronectin to E. coli RNA polymerase signal when
Adr1 is expressed at the surface of E. coli and exposed to vitronectin in the
presence of increasing concentrations of heparin or salt. (C,D) Densitometric
analysis of vitronectin to OmpB signal when vitronectin is exposed to R. conorii in
the presence of increasing concentrations of heparin or salt. A one-way ANOVA
with a Newman-Keuls post hoc test was performed on all data. ∗Represent a p ≤
0.05 and is considered significant. ns represents no significance.
Supplemental Figure 2 | Expression of Adr1 loop 3 mutants in E. coli
BL21(DE3). Western immunoblot analysis of whole cell lysates for each mutant
constructed within loop 3 using anti-Adr1.
Supplemental Figure 3 | Expression of Adr1 loop 4 mutants in E. coli
BL21(DE3). Western immunoblot analysis of whole cell lysates for each mutant
constructed within loop 4 using anti-Adr1.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 10 March 2017 | Volume 7 | Article 61
Fish et al. Characterization of Adr1-Vitronectin Interactions
Supplemental Figure 4 | Confirmation of expression of mutant Adr1
proteins at the outer-membrane of E. coli. Western immune blot analysis of
whole cell lysates (WCL), sarkosyl soluable/inner membrane proteins (IM) and
outer membrane fractions (OM). An Adr1 derivative containing only loop 4
(JP01-L4) was used as a positive control and the empty vector (pET22b) was
used as the negative control. Representative constructs of serum resistant (AF8)
and serum-sensitive (AF17) and phenotypes are presented.
Supplemental Table 1 | Table of primers used for site-directed
mutagenesis. Forward, reverse and screening primers are listed for each lysine
to alanine mutant that was created in this body of work.
REFERENCES
Bartra, S. S., Ding, Y., Fujimoto, L. M., Ring, J. G., Jain, V., Ram, S., et al. (2015).
Yersinia pestis uses the Ail outer membrane protein to recruit vitronectin.
Microbiology 161, 2174–2183. doi: 10.1099/mic.0.000179
Blom, A. M., Hallstrom, T., and Riesbeck, K. (2009). Complement evasion
strategies of pathogens-acquisition of inhibitors and beyond. Mol. Immunol.
46, 2808–2817. doi: 10.1016/j.molimm.2009.04.025
Chan, Y. G., Cardwell, M. M., Hermanas, T. M., Uchiyama, T., and Martinez, J.
J. (2009). Rickettsial outer-membrane protein B (rOmpB) mediates bacterial
invasion through Ku70 in an actin, c-Cbl, clathrin and caveolin 2-dependent
manner. Cell. Microbiol. 11, 629–644. doi: 10.1111/j.1462-5822.2008.01279.x
Chan, Y. G., Riley, S. P., Chen, E., and Martinez, J. J. (2011). Molecular basis of
immunity to Rickettsial infection conferred through outer membrane protein
B. Infect. Immun. 79, 2303–2313. doi: 10.1128/IAI.01324-10
da Silva, L. B., Miragaia Ldos, S., Breda, L. C., Abe, C. M., Schmidt, M. C.,
Moro, A. M., et al. (2015). Pathogenic Leptospira species acquire factor H
and vitronectin via the surface protein LcpA. Infect. Immun. 83, 888–897.
doi: 10.1128/IAI.02844-14
Engelberg, H. (1961). Plasma heparin levels in normal man. Circulation 23,
578–581. doi: 10.1161/01.CIR.23.4.578
Gandhi, A., Balmer, P., and York, L. J. (2016). Characteristics of a new
meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp;
Trumenba(R)). Postgrad. Med. 128, 548–556. doi: 10.1080/00325481.2016.
1203238
Griffiths, N. J., Hill, D. J., Borodina, E., Sessions, R. B., Devos, N. I., Feron, C. M.,
et al. (2011). Meningococcal surface fibril (Msf) binds to activated vitronectin
and inhibits the terminal complement pathway to increase serum resistance.
Mol. Microbiol. 82, 1129–1149. doi: 10.1111/j.1365-2958.2011.07876.x
Hallstrom, T., Blom, A. M., Zipfel, P. F., and Riesbeck, K. (2009). Nontypeable
Haemophilus influenzae protein E binds vitronectin and is important for serum
resistance. J. Immunol. 183, 2593–2601. doi: 10.4049/jimmunol.0803226
Hallstrom, T., Singh, B., Kraiczy, P., Hammerschmidt, S., Skerka, C., Zipfel,
P. F., et al. (2016). Conserved patterns of microbial immune escape:
pathogenic microbes of diverse origin target the human terminal complement
inhibitor vitronectin via a single common motif. PLoS ONE 11:e0147709.
doi: 10.1371/journal.pone.0147709
Hallstrom, T., Trajkovska, E., Forsgren, A., and Riesbeck, K. (2006). Haemophilus
influenzae surface fibrils contribute to serum resistance by interacting with
vitronectin. J. Immunol. 177, 430–436. doi: 10.4049/jimmunol.177.1.430
Hallstrom, T., Uhde, M., Singh, B., Skerka, C., Riesbeck, K., and Zipfel, P. F.
(2015). Pseudomonas aeruginosa uses dihydrolipoamide dehydrogenase (Lpd)
to bind to the human terminal pathway regulators vitronectin and clusterin
to inhibit terminal pathway complement attack. PLoS ONE 10:e0137630.
doi: 10.1371/journal.pone.0137630
Hancock, R. E., and Nikaido, H. (1978). Outer membranes of gram-negative
bacteria. XIX. Isolation from Pseudomonas aeruginosa PAO1 and use in
reconstitution and definition of the permeability barrier. J. Bacteriol. 136,
381–390.
Leduc, I., Olsen, B., and Elkins, C. (2009). Localization of the domains
of the Haemophilus ducreyi trimeric autotransporter DsrA involved
in serum resistance and binding to the extracellular matrix proteins
fibronectin and vitronectin. Infect. Immun. 77, 657–666. doi: 10.1128/IAI.
00819-08
Leroy-Dudal, J., Gagniere, H., Cossard, E., Carreiras, F., and Di Martino, P. (2004).
Role of alphavbeta5 integrins and vitronectin in Pseudomonas aeruginosa
PAK interaction with A549 respiratory cells. Microbes Infect. 6, 875–881.
doi: 10.1016/j.micinf.2004.05.004
Liang, O. D., Preissner, K. T., and Chhatwal, G. S. (1997). The hemopexin-
type repeats of human vitronectin are recognized by Streptococcus pyogenes.
Biochem. Biophys. Res. Commun. 234, 445–449. doi: 10.1006/bbrc.1997.
6663
Madico, G., Welsch, J. A., Lewis, L. A., McNaughton, A., Perlman, D.
H., Costello, C. E., et al. (2006). The meningococcal vaccine candidate
GNA1870 binds the complement regulatory protein factor H and enhances
serum resistance. J. Immunol. 177, 501–510. doi: 10.4049/jimmunol.1
77.1.501
Otterdal, K., Portillo, A., Astrup, E., Ludviksen, J. K., Schjalm, C., Raoult, D.,
et al. (2016). Rickettsia conorii is a potent complement activator in vivo and
combined inhibition of complement and CD14 is required for attenuation
of the cytokine response ex vivo. Clin. Microbiol. Infect. 22, 734.e731–e736.
doi: 10.1016/j.cmi.2016.05.010
Riley, S. P., Fish, A. I., Garza, D. A., Banajee, K. H., Harris, E. K., del
Piero, F., et al. (2016). Nonselective persistence of a Rickettsia conorii
extrachromosomal plasmid during mammalian infection. Infect. Immun. 84,
790–797. doi: 10.1128/IAI.01205-15
Riley, S. P., Patterson, J. L., and Martinez, J. J. (2012). The Rickettsial OmpB beta-
peptide of Rickettsia conorii is sufficient to facilitate factor H-mediated serum
resistance. Infect. Immun. 80, 2735–2743. doi: 10.1128/IAI.00349-12
Riley, S. P., Patterson, J. L., Nava, S., and Martinez, J. J. (2014). Pathogenic
Rickettsia species acquire vitronectin from human serum to promote
resistance to complement-mediated killing. Cell. Microbiol. 16, 849–861.
doi: 10.1111/cmi.12243
Sa, E. C. C., Griffiths, N. J., and Virji, M. (2010). Neisseria meningitidis Opc
invasin binds to the sulphated tyrosines of activated vitronectin to attach
to and invade human brain endothelial cells. PLoS Pathog. 6:e1000911.
doi: 10.1371/journal.ppat.1000911
Seib, K. L., Scarselli, M., Comanducci, M., Toneatto, D., and Masignani,
V. (2015). Neisseria meningitidis factor H-binding protein fHbp: a key
virulence factor and vaccine antigen. Expert Rev. Vaccines 14, 841–859.
doi: 10.1586/14760584.2015.1016915
Singh, B., Blom, A. M., Unal, C., Nilson, B., Morgelin, M., and Riesbeck,
K. (2010a). Vitronectin binds to the head region of Moraxella catarrhalis
ubiquitous surface protein A2 and confers complement-inhibitory
activity. Mol. Microbiol. 75, 1426–1444. doi: 10.1111/j.1365-2958.2010.
07066.x
Singh, B., Jalalvand, F., Morgelin, M., Zipfel, P., Blom, A. M., and Riesbeck, K.
(2011).Haemophilus influenzae protein E recognizes the C-terminal domain of
vitronectin and modulates the membrane attack complex. Mol. Microbiol. 81,
80–98. doi: 10.1111/j.1365-2958.2011.07678.x
Singh, B., Su, Y. C., and Riesbeck, K. (2010b). Vitronectin in bacterial pathogenesis:
a host protein used in complement escape and cellular invasion.Mol. Microbiol.
78, 545–560. doi: 10.1111/j.1365-2958.2010.07373.x
Stockmann, A., Hess, S., Declerck, P., Timpl, R., and Preissner, K. T. (1993).
Multimeric vitronectin. Identification and characterization of conformation-
dependent self-association of the adhesive protein. J. Biol. Chem. 268,
22874–22882.
Su, Y. C., Jalalvand, F., Morgelin, M., Blom, A. M., Singh, B., and Riesbeck,
K. (2013). Haemophilus influenzae acquires vitronectin via the ubiquitous
Protein F to subvert host innate immunity. Mol. Microbiol. 87, 1245–1266.
doi: 10.1111/mmi.12164
Vogt, J., and Schulz, G. E. (1999). The structure of the outer membrane protein
OmpX from Escherichia coli reveals possiblemechanisms of virulence. Structure
7, 1301–1309. doi: 10.1016/S0969-2126(00)80063-5
Voss, S., Hallstrom, T., Saleh, M., Burchhardt, G., Pribyl, T., Singh, B., et al. (2013).
The choline-binding protein PspC of Streptococcus pneumoniae interacts with
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 11 March 2017 | Volume 7 | Article 61
Fish et al. Characterization of Adr1-Vitronectin Interactions
the C-terminal heparin-binding domain of vitronectin. J. Biol. Chem. 288,
15614–15627. doi: 10.1074/jbc.M112.443507
Walker, D. H. (1997). Endothelial-target Rickettsial infection. Lab. Anim. Sci. 47,
483–485.
Walker, D. H., and Gear, J. H. (1985). Correlation of the distribution of Rickettsia
conorii, microscopic lesions, and clinical features in South African tick bite
fever. Am. J. Trop. Med. Hyg. 34, 361–371.
Walker, D. H., Hudnall, S. D., Szaniawski, W. K., and Feng, H. M.
(1999). Monoclonal antibody-based immunohistochemical diagnosis of
rickettsialpox: the macrophage is the principal target. Mod. Pathol. 12,
529–533.
Walker, D. H., and Ismail, N. (2008). Emerging and re-emerging rickettsioses:
endothelial cell infection and early disease events. Nat. Rev. Microbiol. 6,
375–386. doi: 10.1038/nrmicro1866
Walker, D. H., Popov, V. L., Wen, J., and Feng, H. M. (1994). Rickettsia conorii
infection of C3H/HeN mice. A model of endothelial-target rickettsiosis. Lab
Invest 70, 358–368.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Fish, Riley, Singh, Riesbeck and Martinez. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 12 March 2017 | Volume 7 | Article 61
